# Hangzhou Binjiang 5050 Fund

> Hangzhou Binjiang 5050 Fund is a VC fund backing Medical and Biotechnology. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Jun 2025
- Lead investor: 0%
- Last updated: Aug 2026

Hangzhou Binjiang 5050 Fund is an investment fund.

## Contacts

5 contacts available for Hangzhou Binjiang 5050 Fund. Shizune tracks 1 team members at Hangzhou Binjiang 5050 Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/hangzhou-binjiang-5050-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 67% |
| Biotechnology | 2 | 67% |
| Hospital | 1 | 33% |
| Biopharma | 1 | 33% |
| Therapeutics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Angel | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Chen Yichao | Investor | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Jingjiahang | Jingjiahang is a cutting-edge biopharmaceutical company dedicated to the pioneering research, development, and commercialization of innovative new targeted radiopharmaceuticals. With a deep commitment to advancing precision medicine, Jingjiahang focuses on creating highly effective therapeutic solutions that are specifically designed to target andtreat various types of cancer and other serious diseases. |  | Angel | Jun 13, 2025 |  |
| Imbioray | Imbioray is a biotechnology company that specializes in cellular immunotherapy for tumors and immune diseases. The company engages in the development of global CAR-NK and tiNK cell therapy drugs and is committed to solving the treatment of clinically unmet diseases. | $13.5M | Series A | Jan 21, 2025 |  |
| St Phi Therapeutics | Yizun Biotechnology is a cutting-edge immune cell therapy company that has developed many unique platform technologies, including solid tumor treatment and allogeneic universal cell therapy. | $13.8M | Series A | Apr 15, 2024 |  |

3 of 3 investments shown.

## Co-investors
- [Tailong Investment](https://shizune.co/investors/profile/tailong-investment) — VC Fund, 2 deals together
- Hangshi Asset Management — VC Fund, 1 deal together
- Huayi Capital — VC Fund, 1 deal together
- [Sinowisdom](https://shizune.co/investors/profile/sinowisdom) — VC Fund, 1 deal together
- Sunzi Technology — VC Fund, 1 deal together
- [Taiyu Investment](https://shizune.co/investors/profile/taiyu-investment) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Hangzhou Binjiang 5050 Fund invest in?

Hangzhou Binjiang 5050 Fund invests primarily in Medical, Biotechnology and Hospital startups, most often at Series A and Angel stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Hangzhou Binjiang 5050 Fund?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Hangzhou Binjiang 5050 Fund?

The team at Hangzhou Binjiang 5050 Fund includes Chen Yichao (Investor). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co